CannabisNewsBreaks

WednesdayJan 03, 2018 10:40 am

CBDNewsBreaks – Global Payout, Inc. (GOHE) Subsidiary Appoints New CEO

Payment solutions company Global Payout, Inc. (OTC: GOHE), through majority-owned subsidiary MoneyTrac Technology, Inc. (“MTRAC”), this morning announced the promotion of Vanessa Luna to the position of chief executive officer, effective January 1, 2018. Luna previously served as MTRAC’s COO for nine months, playing a key role in positioning the company for its anticipated expansion within the booming cannabis industry. “I mentioned in the 2017 year-end review that was distributed last week that MoneyTrac is very much on the verge of significant growth from a revenue perspective,” James Hancock, MTRAC’s chairman of the board, stated in the news release. “This…

Continue Reading

WednesdayJan 03, 2018 9:43 am

CBDNewsBreaks – PotNetwork Holding, Inc. (POTN) Recaps 2017 Successes in Update

PotNetwork Holding, Inc. (OTC: POTN) this morning shared its outlook on what it called a “solid year of record breaking success” in 2017. Per the news release, the company’s management team has established “a solid infrastructure for success” since acquiring First Capital Venture Co. and Diamond CBD. Highlights related to these corporate milestones include strengthening the company’s value and achieving share appreciation from $0.01 in January 2017 to $0.10 in December 2017. PotNetwork also established an esteemed advisory board to aid in the research and development of new products, brought on a distinguished Florida physician as its chief executive officer…

Continue Reading

TuesdayJan 02, 2018 12:05 pm

CBDNewsBreaks – EVIO, Inc. (EVIO) Acquires Stake in C3 Labs, LLC

EVIO, Inc. (OTCQB: EVIO), a life sciences company and leading provider of quality control testing and advisory services to the regulated cannabis industry, this morning announced that it has completed the acquisition of 60 percent of C3 Labs, LLC, one of the nation’s first cannabis-focused contract research organizations. EVIO also maintains the option to purchase the remaining ownership stake in C3 Labs for an initial period of three years, subject to C3 member approval. “The addition of C3 Labs to the EVIO network is a tremendous milestone for EVIO Inc.,” William Waldrop, CEO of EVIO, stated in the news release.…

Continue Reading

TuesdayJan 02, 2018 11:33 am

CBDNewsBreaks – India Globalization Capital, Inc.’s (NYSE: IGC) Cannabis-based Eating Disorder Treatment Anticipated for PCT Filing in February

India Globalization Capital (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, has recently developed IGC-506 for the treatment of multiple types of eating disorders in humans, as well as animals in the veterinary market. The company expects to file a Patent Cooperation Treaty (“PCT”) application by February 28, 2018. PCT is an international patent filing effective in numerous foreign countries. An article discussing this reads: “IGC-506 is a combination therapy drug, developed from cannabis-extracts and other compounds, designed to treat multiple types of eating disorders. Cannabinoids are chemical compounds that exert a range…

Continue Reading

TuesdayJan 02, 2018 11:12 am

CBDNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Provides Post-Holiday Update on Baijiu Sales

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning offered shareholders a post-holiday update on CBD Biotechnology Co. Ltd.’s Yantai 1985 baijiu sales. Through a partnership with a proven leader in the Chinese baijiu market, the company’s wholly-owned foreign enterprise has commenced an initial marketing campaign on Chinese mobile app Today’s Headlines that it anticipates will drive revenues of approximately $1.8 million in 2018. These projections are supported by the early success of CBD Biotechnology’s advertising efforts. Notably, the digital ad campaign generated revenues of over $29,000 in its first week. “The marketing-to-revenue ratio for the initial sales campaign on…

Continue Reading

TuesdayJan 02, 2018 10:32 am

CBDNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Receives Cannabis Oil Production License from Health Canada

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced that it has been licensed by Health Canada to produce medical cannabis oils. Per the update, Health Canada will conduct a final inspection when ABcann has saleable extracted finished products. ABcann expects to complete this process in the first quarter of 2018. “Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed,” Barry Fishman, CEO of ABcann, stated in the news release. “The expansion and innovation of our product lines…

Continue Reading

TuesdayJan 02, 2018 9:44 am

CBDNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Adds Dr. Brian O’Connor to Advisory Board

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced the addition of Dr. Brian O’Connor, a consultant in respiratory medicine, to its advisory board. Per the update, O’Connor is a clinical expert in the areas of asthma, chronic obstructive pulmonary disease (“COPD”), allergic disease and lung cancer. He is also an active clinical researcher committed to investigating new treatment strategies in airways disease. “Dr. O’Connor brings a great reputation of clinical excellence and scholarly research,” Dr. Lui Franciosi, CEO of Veritas, stated in the news release. “He will advise us on…

Continue Reading

FridayDec 29, 2017 12:05 pm

CBDNewsBreaks – Skinvisible, Inc. (SKVI) Prepares to Address Killer Drug Epidemic Through Proposed Merger Agreement

Topical and transdermal product development company Skinvisible (OTCQB: SKVI) recently signed a letter of intent regarding a proposed merger with Quoin Pharmaceuticals Limited. The two companies intend to work together to address the opioid epidemic plaguing America. An article discussing this reads: “There are increased incentives and growing public and FDA/government demands to address the crisis. Innovators vying to meet critical needs and to combat the opioid issue with alternative, non-addictive and effective products include Skinvisible, Inc. (OTCQB: SKVI) and Quoin Pharmaceuticals Limited. As announced earlier this month, the two companies have entered a Letter of Intent for a proposed…

Continue Reading

FridayDec 29, 2017 11:57 am

CBDNewsBreaks – Marijuana Company of America, Inc. (MCOA) Positioned for Bright Future Amid Support from Recognized Health Organization

With a portfolio of operating subsidiaries, partnerships and joint ventures, Marijuana Company of America (OTC: MCOA) is slated to exploit the ever-growing cannabis market as support of the industry continues to grow among recognized health organizations. An article discussing this reads: “The World Health Organization (“WHO”) officially recommended on December 14, 2017, that the chemical compound cannabidiol (CBD) no longer be internationally scheduled as a controlled substance. WHO has issued a preliminary report that found CBD to be non-addictive and generally safe. ... The wholly-owned subsidiary of Marijuana Company of America Inc. (OTC: MCOA), hempSMART™, Inc. is an affiliate marketing…

Continue Reading

FridayDec 29, 2017 9:44 am

CBDNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Visits Clinical Trial Facility in San Juan, Puerto Rico

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced that it has completed a prestudy visit of the Fundación de Investigación (“FDI”) facilities in San Juan, Puerto Rico. Per the release, this will be the site where the company’s research arm, Cannevert Therapeutics Ltd. (“CTL”), will be conducting its first human study of CTL-X, a cannabis strain targeting the pain management market. Speaking about the FDI clinical trial facility in this morning's update, Veritas CEO Lui Franciosi stated, “I was very impressed by their Phase I and Phase II-III clinical trial…

Continue Reading